Shattuck Labs, Inc. (STTK)
| Market Cap | 585.00M +1,221.6% |
| Revenue (ttm) | 1,000,000 -82.5% |
| Net Income | -48.81M |
| EPS | -0.70 |
| Shares Out | 75.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,921 |
| Open | 7.75 |
| Previous Close | 7.65 |
| Day's Range | 7.43 - 8.00 |
| 52-Week Range | 0.71 - 8.33 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 10.00 (+29.2%) |
| Earnings Date | May 1, 2026 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical... [Read more]
Financial Performance
In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for STTK stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 29.20% from the latest price.
News
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of po...
Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference
A novel DR3 blocking antibody program aims to overcome immunogenicity and efficacy limitations of TL1A blockers in IBD. Phase I data for SL-325 will be released in Q2, with a phase IIb Crohn's trial starting in Q3. Bispecifics and lifecycle management strategies are also advancing.
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-cl...
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targ...
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of nove...
Shattuck Labs Transcript: Evercore ISI 8th Annual HealthCONx Conference
Targeting the TL1A receptor may offer superior safety and efficacy over ligand-blocking due to reduced immunogenicity and stable receptor expression. Phase 1 data in healthy volunteers support a differentiated profile, with rapid advancement to phase 2 and combination strategies planned.
Shattuck Labs Transcript: Piper Sandler 37th Annual Healthcare Conference
SL-325, a DR3 blocking antibody, aims to offer more durable and safer inhibition of the TL1A/DR3 axis in inflammatory diseases compared to TL1A blockers. Phase I data will be shared in early 2026, with phase II trials and funding secured through 2029.
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company's lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory b...
Shattuck Labs to Participate in Upcoming December Investor Conferences
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of nove...
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointment...
Shattuck Labs Transcript: The United European Gastroenterology (UEG) Congress UEG Week 2025
DR3 is a stable, broadly expressed target in IBD, offering potential efficacy and safety advantages over TL1A blockade. SL-325, a high-affinity DR3 antagonist, is advancing through phase I with phase II trials planned in IBD and other autoimmune diseases. First clinical data are expected in the first half of 2026.
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disea...
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 –...
Shattuck Labs Transcript: 24th Annual Needham Virtual Healthcare Conference
A novel DR3-targeting antibody program aims to improve IBD remission rates by leveraging unique receptor biology and overcoming immunogenicity challenges seen with TL1A antibodies. Phase one trials are imminent, with a parallel half-life extended version in development to enable less frequent dosing.
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor ne...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-cla...
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxic...
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necro...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...
Shattuck Labs Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
The presentation highlighted the scientific rationale for targeting DR3 in inflammatory bowel diseases, emphasizing its broader and more stable expression compared to TL1A. The lead DR3 antibody, SL-325, is entering clinical trials in 2024, with initial data expected by year-end and a key presentation at the European Crohn's and Colitis Congress.